USE OF RECOMBINANT HUMAN TSH IN THYROID CANCER PATIENTS

目前，分化良好的甲状腺癌患者 接受过几乎全甲状腺切除术的患者， 全身I131扫描和I131治疗，如果甲状腺残留和/或 在扫描中发现转移。在这些治疗之前， 标准治疗要求停止甲状腺激素替代治疗， 刺激优化I131摄取所需内源性TSH分泌， 残留甲状腺组织和/或转移。这种方法可能是 对患有充血性心脏病等疾病的患者有危险 故障，这可能会受到不利影响的长期状态， 甲状腺功能减退本研究的目的是为患者提供 注射重组TSH（Thyrogen）以避免甲状腺癌 在获得甲状腺扫描之前， 甲状腺癌残留的指导和治疗。的产物 重组技术，Thryogen可以支持TSH依赖的代谢 活性而不被识别为抗原实体。到目前为止， 两名患者已经成功地用甲状腺素治疗， 这个协议。两人均未出现任何不良反应， 甲状腺素给药允许可视化残留和/或 全身扫描和用I131治疗的转移性甲状腺组织。

At the present time, patients with well differentiated thyroid cancer who have undergone a near total thyroidectomy are frequently subjected to a total body I131 scan and I131 treatment if thyroid remnants and/or metastasis are identified on the scan. Prior to these treatments, the standard of care requires withrawal of thyroid hormone replacement to stimulate endogenous TSH secretion needed to optimize I131 uptake by residual thyroid tissue and/or metastasis. This approarch may be hazardous in patients with medical consitions such as congestive heart failures, which may be adversely affected by a prolonged state of hypothyroidism. The purpose of this study is to offer patients with thyroid cancer an injection of recombinent TSH (Thyrogen) to avoid prolonged hypothyroidism prior to obtaining a thyroid scan for the direction and treatment of residual thyroid cancer. As a product of recombinent technology, Thryrogen could support TSH-dependent metabolic activities without being recognized as an antigenic entity. Until now, two patients have been successfully treated with thyrogen according to this protocol. Neither experienced any adverse reaction and in both thyrogen administration allowed visualization of residual and/or metastatic thyroid tissue on total body scan and treatment with I131.